Table 2.
Observational studies of sorafenib in RAI-R DTC from 2010–2013
| Author, year of observational study | Thyroid CA – inclusion criteria | Drug (intervention) | Responses | Safety | Observations |
|---|---|---|---|---|---|
| Marotta et al,25 2013 | Progressive RAI-R DTC n=17 | Sorafenib 400 mg bid | 30% PR, 41% SD | Three died from bleeding complications and two died from myocardial infarction | Best response in LN and lung lesions. Baseline TG level and TG response correlated to treatment response |
| de la Fouchardiere et al,16 2013 | Advanced RAI-R DTC n=45 | Sorafenib (unspecified dose) | PR 29%, mPFS 6.7 months |
NA | Responsiveness: liver > lung > lymph node >bone > pleura |
| Chen et al,17 2011 | RAI-R PTC n=9 | Sorafenib 200 mg bid | PR 33%, SD 44%, mPFS 42 weeks | NA | Decreased serum TG by 60% within 12 weeks |
| Cabanillas et al,28 2010 | RAI-R DTC with evidence of PD n=13 | Sorafenib 400 mg | 20% PR, 60% SD, and 20% PD, clinical benefit 80%, mPFS 19 months, mOS not reached | NA | Responsiveness: lung (−22% change) > LN (0% change) > pleural disease/bone (PD) |
Abbreviations: bid, twice daily; CA, cancer; DTC, differentiated thyroid cancer; LN, lymph node; mPFS, median progression-free survival; mOS, median overall survival; NA, not applicable; PD, poorly differentiated thyroid carcinoma; PR, partial response; PTC, papillary thyroid carcinoma; RAI, radioactive iodine; SD, stable disease; TG, thyroglobulin.